News
Public · Published
Metropolis Healthcare Q2: Net profit jumps 43% on higher test volumes, specialty and B2C growth
Metropolis Healthcare reported a 43.2% year-on-year rise in net profit to ₹75.3 crore for the second quarter. Revenue rose 15.8% to ₹496.8 crore. Patient volume grew 10% to 4.1 million and test volume rose 11% to 8.7 million.
Published:
Updated:
What happened
Metropolis Healthcare reported a 43.2% year-on-year rise in net profit to ₹75.3 crore for the second quarter. Revenue rose 15.8% to ₹496.8 crore. Patient volume grew 10% to 4.1 million and test volume rose 11% to 8.7 million.
Confirmed
Global impact / market context
Profit growing faster than revenue shows the diagnostic chain is collecting more cash per test while costs stay controlled, so each additional patient adds more to earnings. That higher profit per sale can support reinvestment in specialty testing and expand the customer base.
Analyst inference
Diagnostic companies earn from repeat testing and preventive health checks, so volume and revenue per patient are key drivers. Growth in consumer-direct and specialty testing, which means advanced tests such as genomic and cancer screening, tends to carry better pricing than routine tests.
Analyst inference
What to watch
- Revenue per patient rose 6% to ₹1,221 even without any price increase, so future profit growth depends on higher test volumes and a richer mix of specialty tests. Confirmed
- Watch whether the company sustains double-digit volume growth while keeping cost growth below revenue growth, since that gap is what lifted the profit margin to 27%. Proposed
- If specialty and consumer-direct revenue keep growing faster than routine business, the mix can lift profit per test, but slower patient additions would weaken the volume-led earnings model. Analyst inference
Evidence
- Original source link unavailable